Biopharma
|
July 1, 2025
Fresenius Expands Biosimilars Portfolio with the availability of their denosumab biosimilars in the U.S.
Fresenius Kabi’s fifth and sixth biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) are now available in the U.S. for all approved indications for their respective reference products, Prolia® (denosumab) and Xgeva® (denosumab).